Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease
The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
Using the Braak staging for neurofibrillary changes as an objective indicator of the progression of Alzheimer's disease, we have performed a systematic search for global gene expression changes in the prefrontal cortex during the course of Alzheimer's disease. In the prefrontal cortex, senile plaques and neurofibrillary changes start to appear around Braak stage III, allowing for the detection of changes in gene expression before, during and after the onset of Alzheimer's disease neuropathology. Two distinct patterns of tightly co-regulated groups of genes were observed: (i) an increase in expression in early Braak stages, followed by a decline in expression in later stages (the UPDOWN clusters; containing 865 genes) and (ii) a decrease in expression in early Braak stages, followed by an increase in expression in later stages (the DOWNUP clusters; containing 983 genes). The most profound changes in gene expression were detected between Braak stages II and III, just before or at the onset of plaque pathology and neurofibrillary changes in the prefrontal cortex. We also observed an increase in intracellular beta amyloid staining from Braak stages I to III and a clear decrease in Braak stages IV to VI. These data suggest a link between specific gene expression clusters and Alzheimer's disease-associated neuropathology in the prefrontal cortex. Gene ontology over-representation and functional gene network analyses indicate an increase in synaptic activity and changes in plasticity during the very early pre-symptomatic stage of the disease. In later Braak stages, the decreased expression of these genes suggests a reduction in synaptic activity that coincides with the appearance of plaque pathology and neurofibrillary changes and the clinical diagnosis of mild cognitive impairment. The interaction of the ApoE genotype with the expression levels of the genes in the UPDOWN and DOWNUP clusters demonstrates that the accelerating role of ApoE-ε4 in the progression of Alzheimer's disease is reflected in the temporal changes in gene expression presented here. Since the UPDOWN cluster contains several genes involved in amyloid precursor protein processing and beta amyloid clearance that increase in expression in parallel with increased intracellular beta amyloid load, just before the onset of plaque pathology in the prefrontal cortex, we hypothesize that the temporally orchestrated increase in genes involved in synaptic activity represents a coping mechanism against increased soluble beta amyloid levels. As these gene expression changes occur before the appearance of Alzheimer's disease-associated neuropathology, they provide an excellent starting point for the identification of new targets for the development of therapeutic strategies aimed at the prevention of Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early transcriptomic studies utilizing microarrays revealed alterations in synaptic, immune, and metabolic pathways that appear even before clinical symptoms, underscoring the potential for pre-symptomatic intervention120,125,161.”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [125]
In the citing paper
“and the decreased expression of these synaptic genes in later Braak stages, suggesting a reduction in synaptic activity that coincides with AD neuropathology and cognitive impairment 252.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [252]
In the citing paper
“Systematic search for global gene expression changes in PFC during the course of AD has found a temporally orchestrated increase of genes involved in synaptic activity during the very early pre-symptomatic stage, probably representing a coping mechanism against increased β-amyloid levels, and the decreased expression of these synaptic genes in later Braak stages, suggesting a reduction in synaptic”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [252]
In the citing paper
“Several studies have shown altered gene expression in the post‐mortem brain of cases with AD and related animal models 7, 67, 99.”
From Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome (2016) · cites this paper as [7]
Citations
Cites
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman, F. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0034 · Cited by 20,038
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“We selected the prefrontal cortex (PFC), because it is affected relatively late in the Alzheimer’s disease process (Braak and Braak, 1991).”
BackgroundMethodTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“, 2002), and in several transgenic mouse models for Alzheimer’s disease (Oakley et al., 2006; Oddo et al., 2006).”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 2×
“In addition to ApoE, variations in CLU, PICALM and CR1 have recently been associated with sporadic Alzheimer’s disease (Harold et al., 2009; Lambert et al., 2009).”
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 1×
“Alzheimer’s disease disease progression can be monitored by the presence of tangle-bearing neurons in well-defined brain areas, and is classified into 6 Braak stages (Braak I-VI) (Braak and Braak, 1991; Braak et al., 2006).”
BackgroundGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Improved scoring of functional groups from gene expression data by decorrelating GO graph structure
Alexa, A., Rahnenführer, J., & Lengauer, T. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl140 · Cited by 2,188
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Gene regulation and DNA damage in the ageing human brain
Lu, T., Pan, Y., Kao, S.-Y., Li, C., Kohane, I., Chan, J., & Yankner, B. A. (2004) · Nature · doi:10.1038/nature02661 · Cited by 1,874
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2005) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,687
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644 · cited 1×
“Thus, the combined observation that synaptic activity increases extracellular Aβ levels and that soluble Aβ inhibits synaptic transmission, suggest that under normal physiological conditions, Aβ is part of a negative feedback loop preventing neuronal hyperexcitability (Kamenetz et al., 2003).”
RNA integrity and the effect on the real-time qRT-PCR performance
Fleige, S., & Pfaffl, M. W. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.12.003 · Cited by 1,487
Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294
Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.028 · Cited by 1,265 · cited 1×
“Furthermore, Cirrito et al very elegantly provided direct in vivo evidence for the relation between synaptic activity and interstitial Aβ levels (Cirrito et al., 2005).”
BackgroundBlalock, E. M., Geddes, J. W., Chen, K. C., Porter, N. M., Markesbery, W. R., & Landfield, P. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308512100 · Cited by 1,025
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · cited 2×
“By performing immunohistochemical stainings in sections of the same samples that were used for the microarray experiment using the well-characterized 4G8 antibody which is known to recognize intra- and extracellular Ab (both as a free peptide and as part of APP) (Aho et al., 2010; Christensen et al., 2010; Gouras et a…”
MethodResultFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 1×
“, 2000), is associated with altered CNS glucose metabolism (Wishart et al., 2006; Reiman et al., 2004; Dubelaar et al., 2004) and causes mitochondrial dysfunction (Chang et al.”
BackgroundHoltzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · cited 1×
“, 2003), enhances Aβ deposition (Holtzman et al., 2000), is associated with altered CNS glucose metabolism (Wishart et al.”
BackgroundMahley, R. W., Weisgraber, K. H., & Huang, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600549103 · Cited by 912
Davies, P., Katzman, R., & Terry, R. D. (1980) · Nature · doi:10.1038/288279a0 · Cited by 882
Devi, L., Prabhu, B. M., Galati, D. F., Avadhani, N. G., & Anandatheerthavarada, H. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1469-06.2006 · Cited by 792
SIRT1 Protects against Microglia-dependent Amyloid-β Toxicity through Inhibiting NF-κB Signaling
Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.-F., Kwon, H., Yi, S., Mucke, L., & Gan, L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509329200 · Cited by 740 · cited 1×
“Indeed, SIRT1 protects against microglia-dependent Aβ toxicity by increasing the acetylation of RELA, thereby inhibiting NF-kappaB signaling (Chen et al., 2005).”
BackgroundThe genetic epidemiology of neurodegenerative disease
Bertram, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24761 · Cited by 680
Yankner, B. A., Lu, T., & Loerch, P. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.2.010506.092044 · Cited by 677 · cited 1×
“The main risk factor for sporadic Alzheimer’s disease is age (Yankner et al., 2008).”
BackgroundExperience-driven plasticity of visual cortex limited by myelin and nogo receptor
McGee, A. W., Yang, Y., Fischer, Q. S., Daw, N. W., & Strittmatter, S. M. (2005) · Science · doi:10.1126/science.1114362 · Cited by 643
ApoE genotype accounts for the vast majority of AD risk and AD pathology
Raber, J., Huang, Y., & Ashford, J. W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.023 · Cited by 599
Anandatheerthavarada, H. K., Biswas, G., Robin, M.-A., & Avadhani, N. G. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200207030 · Cited by 571 · cited 1×
“In Tg2576 Alzheimer’s disease mice, Aβ monomers and oligomers are located on mitochondrial membranes in a transmembrane arrested form (Anandatheerthavarada et al., 2003).”
BackgroundLee, J.-Y., Cole, T. B., Palmiter, R. D., Suh, S. W., & Koh, J.-Y. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092034699 · Cited by 430
Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation
Saito, T., Iwata, N., Tsubuki, S., Takaki, Y., Takano, J., Huang, S.-M., Suemoto, T., Higuchi, M., & Saido, T. C. (2005) · Nature Medicine · doi:10.1038/nm1206 · Cited by 361
Tomita, H., Vawter, M. P., Walsh, D. M., Evans, S. J., Choudary, P. V., Li, J., Overman, K. M., Atz, M. E., Myers, R. M., Jones, E. G., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.10.013 · Cited by 331
Chang, S., Ma, T. R., Miranda, R. D., Balestra, M. E., Mahley, R. W., & Huang, Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508254102 · Cited by 319
Barbosa, A. C., Kim, M.-S., Ertunc, M., Adachi, M., Nelson, E. D., McAnally, J., Richardson, J. A., Kavalali, E. T., Monteggia, L. M., Bassel-Duby, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802679105 · Cited by 303
Deuel, T. A. S., Liu, J. S., Corbo, J. C., Yoo, S.-Y., Rorke-Adams, L. B., & Walsh, C. A. (2006) · Neuron · doi:10.1016/j.neuron.2005.10.038 · Cited by 286
Alzheimer’s disease-related alterations in synaptic density: neocortex and hippocampus.
Scheff, S. W., & Price, D. A. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s312 · Cited by 284
A Dynamic Relationship between Intracellular and Extracellular Pools of Aβ
Oddo, S., Caccamo, A., Smith, I. F., Green, K. N., & LaFerla, F. M. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050593 · Cited by 261 · cited 1×
“, 2002), and in several transgenic mouse models for Alzheimer’s disease (Oakley et al., 2006; Oddo et al., 2006).”
BackgroundKoizumi, H., Tanaka, T., & Gleeson, J. G. (2006) · Neuron · doi:10.1016/j.neuron.2005.10.040 · Cited by 259
Intraneuronal Aβ42 accumulation in Down syndrome brain: Original Articles
Mori, C., Spooner, E. T., Wisniewski, K. E., Wisniewski, T. M., Yamaguchi, H., Saido, T. C., Tolan, D. R., Selkoe, D. J., & Lemere, C. A. (2002) · Amyloid · doi:10.3109/13506120208995241 · Cited by 255 · cited 1×
“, 2000) and DS (Gyure et al., 2001; Mori et al., 2002), and in several transgenic mouse models for Alzheimer’s disease (Oakley et al.”
BackgroundIntraneuronal Aβ-Amyloid Precedes Development of Amyloid Plaques in Down Syndrome
Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E., & Troncoso, J. C. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0489-iaapdo · Cited by 248
Katsel, P., Li, C., & Haroutunian, V. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9297-x · Cited by 241
Molecular aging in human prefrontal cortex is selective and continuous throughout adult life
Erraji-Benchekroun, L., Underwood, M. D., Arango, V., Galfalvy, H., Pavlidis, P., Smyrniotopoulos, P., Mann, J. J., & Sibille, E. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.034 · Cited by 236
L1 and NCAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowth
Schmid, R. S., & Maness, P. F. (2008) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2008.07.015 · Cited by 235
Ha, C., Ryu, J., & Park, C. B. (2007) · Biochemistry · doi:10.1021/bi7000032 · Cited by 231 · cited 1×
“Finally, the synaptic zinc transporter ZnT3 releases Zn2+ into the synaptic cleft upon neuronal activity, which can accelerate plaque formation (Ha et al., 2007).”
BackgroundSaneyoshi, T., Wayman, G., Fortin, D., Davare, M., Hoshi, N., Nozaki, N., Natsume, T., & Soderling, T. R. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.016 · Cited by 228
Wilhelmus, M. M. M., Otte‐Höller, I., Wesseling, P., De Waal, R. M. W., Boelens, W. C., & Verbeek, M. M. (2006) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00689.x · Cited by 222
Ji, Y., Gong, Y., Gan, W., Beach, T., Holtzman, D. M., & Wisniewski, T. (2003) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.007 · Cited by 189 · cited 1×
“Amongst others, ApoE-ε4 negatively affects neurite outgrowth and remodeling (Nathan et al., 2002; Ji et al., 2003), enhances Aβ deposition (Holtzman et al.”
BackgroundReduced lumbar CSF somatostatin in levels in Alzheimer's disease
Wood, P. L., Etienne, P., Lal, S., Gauthier, S., Cajal, S., & Nair, N. P. V. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90099-6 · Cited by 181
Lukiw, W. J. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000023615.89699.63 · Cited by 171
Familial risk for Alzheimer's disease alters fMRI activation patterns
Bassett, S. S., Yousem, D. M., Cristinzio, C., Kusevic, I., Yassa, M. A., Caffo, B. S., & Zeger, S. L. (2006) · Brain · doi:10.1093/brain/awl089 · Cited by 171
Clayton, E. L., Anggono, V., Smillie, K. J., Chau, N., Robinson, P. J., & Cousin, M. A. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1976-09.2009 · Cited by 170
Chapter 20 Neuropathological hallmarks of Alzheimer's and Parkinson's diseases
Braak, H., de Vos, R. A. I., Jansen, E. N. H., Bratzke, H., & Braak, E. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)64021-2 · Cited by 169
Nathan, B. P., Jiang, Y., Wong, G. K., Shen, F., Brewer, G. J., & Struble, R. G. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03367-4 · Cited by 169
Regeur, L., Badsberg Jensen, G., Pakkenberg, H., Evans, S. M., & Pakkenberg, B. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90030-2 · Cited by 167
Zloković, B. V. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00310-4 · Cited by 152
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152 · cited 1×
“96 ApoE-ε4 alleles are known to progress faster from MCI to Alzheimer’s disease (Belbin et al., 2007; Craft et al., 1998).”
BackgroundNeuronal protection by sirtuins in Alzheimer's disease
Anekonda, T. S., & Reddy, P. H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03492.x · Cited by 150
Evidence for CALM in Directing VAMP2 Trafficking
Harel, A., Wu, F., Mattson, M. P., Morris, C. M., & Yao, P. J. (2008) · Traffic · doi:10.1111/j.1600-0854.2007.00694.x · Cited by 144
Wishart, H. A., Saykin, A. J., Rabin, L. A., Santulli, R. B., Flashman, L. A., Guerin, S. J., Mamourian, A. C., Belloni, D. R., Rhodes, C. H., & McAllister, T. W. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1603 · Cited by 144
Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years
Mondadori, C. R. A., Buchmann, A., Mustovic, H., Schmidt, C. F., Boesiger, P., Nitsch, R. M., Höck, C., Streffer, J. R., & Henke, K. (2006) · Brain · doi:10.1093/brain/awl266 · Cited by 134
The decline in synapses and cholinergic activity is asynchronous in Alzheimer’s disease
Tiraboschi, P., Hansen, L. A., Alford, M. F., Masliah, E., Thal, L. J., & Corey‐Bloom, J. (2000) · Neurology · doi:10.1212/wnl.55.9.1278 · Cited by 130
Accumulation of intraneuronal Aβ correlates with ApoE4 genotype
Christensen, D. Z., Schneider-Axmann, T., Lucassen, P. J., Bayer, T. A., & Wirths, O. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0666-1 · Cited by 120
Kojro, E., Postina, R., Buro, C., Meiringer, C., Gehrig‐Burger, K., & Fahrenholz, F. (2006) · The FASEB Journal · doi:10.1096/fj.05-4812fje · Cited by 118 · cited 1×
“PACAP regulates Aβ levels by promoting the non-amyloidogenic alpha- secretase pathway of APP processing (Kojro et al., 2006), and is capable of attenuating Aβ42-mediated cell death in PC12 cells (Onoue et al.”
BackgroundTing, J. T., Kelley, B. G., Lambert, T. J., Cook, D. G., & Sullivan, J. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608807104 · Cited by 114
The neuropeptide PACAP attenuates β-amyloid (1–42)-induced toxicity in PC12 cells
Onoue, S., Endo, K., Ohshima, K., Yajima, T., & Kashimoto, K. (2002) · Peptides · doi:10.1016/s0196-9781(02)00085-2 · Cited by 113
Spasic, D., Raemaekers, T., Dillen, K., Declerck, I., Baert, V., Serneels, L., Füllekrug, J., & Annaert, W. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200609180 · Cited by 108
van de Nes, J. A. P., Kamphorst, W., Ravid, R., & Swaab, D. F. (1998) · Acta Neuropathologica · doi:10.1007/s004010050872 · Cited by 106
Self-citationEndoplasmic reticulum retention of the γ‐secretase complex component Pen2 by Rer1
Kaether, C., Scheuermann, J. C., Faßler, M., Zilow, S., Shirotani, K., Valkova, C., Novak, B., Kacmar, S., Steiner, H., & Haass, C. (2007) · EMBO Reports · doi:10.1038/sj.embor.7401027 · Cited by 94
Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosis
Bitoun, M., Durieux, A., Prudhon, B., Bevilacqua, J. A., Herlédan, A., Sakanyan, V. A., Urtizberea, J. A., Cartier, L., Romero, N. B., & Guicheney, P. (2009) · Human Mutation · doi:10.1002/humu.21086 · Cited by 92
Molecular and Cellular Mechanisms for Alzheimers Disease:Understanding APP Metabolism
Zhang, Y., & Xu, H. (2007) · Current Molecular Medicine · doi:10.2174/156652407782564462 · Cited by 90
Shemer, I., Holmgren, C. D., Min, R., Fülöp, L., Zilberter, M. Y., Sousa, K. M., Farkas, T., Härtig, W., Penke, B., Burnashev, N., et al. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04733.x · Cited by 89
Reddy, P. H., & McWeeney, S. K. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.014 · Cited by 83
The Subcellular Localizations of Atypical Synaptotagmins III and VI
Butz, S., Fernandez-Chacon, R., Schmitz, F., Jahn, R., & Südhof, T. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18290 · Cited by 80
May, C., Rapoport, S. I., Tomai, T. P., Chrousos, G. P., & Gold, P. W. (1987) · Neurology · doi:10.1212/wnl.37.3.535 · Cited by 76
Aho, L., Pikkarainen, M., Hiltunen, M., Leinonen, V., & Alafuzoff, I. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091681 · Cited by 71 · cited 3×
“It should be noted that 4G8 immunoreactivity might be due to other APP cleavage products that contain the Ab peptide, and not the free Ab peptide itself (Aho et al., 2010).”
BackgroundMethodResultPizzi, M., Sarnico, I., Lanzillotta, A., Battistin, L., & Spano, P. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06767.x · Cited by 63
LINGO-1 Interacts with WNK1 to Regulate Nogo-induced Inhibition of Neurite Extension
Zhang, Z., Xu, X., Zhang, Y., Zhou, J., Yu, Z., & He, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808751200 · Cited by 61
Belbin, O., Dunn, J. L., Ling, Y., Morgan, L., Chappell, S., Beaumont, H., Warden, D., Smith, D. A., Kalsheker, N., & Morgan, K. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm171 · Cited by 59
Hidalgo, J., Penkowa, M., Espejo, C., Martínez-Cáceres, E. M., Carrasco, J., Quintana, A., Molinero, A., Florit, S., Giralt, M., & Aznar, A. O. (2006) · Experimental Biology and Medicine · doi:10.1177/153537020623100902 · Cited by 56
Rnd1 Regulates Axon Extension by Enhancing the Microtubule Destabilizing Activity of SCG10
Li, Y., Ghavampur, S., Bondallaz, P., Will, L., Grenningloh, G., & ̈schel, A. W. P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m808126200 · Cited by 52
Stonins—Specialized Adaptors for Synaptic Vesicle Recycling and Beyond?
Maritzen, T., Podufall, J., & Haucke, V. (2010) · Traffic · doi:10.1111/j.1600-0854.2009.00971.x · Cited by 50
Dubelaar, E. J. G., Verwer, R. W. H., Hofman, M. A., van Heerikhuize, J. J., Ravid, R., & Swaab, D. F. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.2.159 · Cited by 50
Self-citationDiamandis, E. P., Scorilas, A., Kishi, T., Blennow, K., Luo, L., Soosaipillai, A. R., RADEMAKER, A. W., & Sjögren, M. J. C. (2003) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2003.11.012 · Cited by 49
Erythrocyte Complement Receptors
Birmingham, D. J. (1995) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v15.i2.20 · Cited by 45
Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells
Renbaum, P., Beeri, R., Gabai, E., Amiel, M., Gal, M., Ehrengruber, M. U., & Levy‐Lahad, E. (2003) · Gene · doi:10.1016/s0378-1119(03)00766-2 · Cited by 45
Salins, P. B., He, Y., Olson, K. L., Glazner, G. W., Kashour, T. S., & Amara, F. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.10.025 · Cited by 41
Altered fMRI activation during mental rotation in those at genetic risk for Alzheimer disease
Yassa, M. A., Verduzco, G., Cristinzio, C., & Bassett, S. S. (2008) · Neurology · doi:10.1212/01.wnl.0000312288.45119.d1 · Cited by 35
Dubelaar, E. J. G., Mufson, E. J., ter Meulen, W. G., van Heerikhuize, J. J., Verwer, R. W. H., & Swaab, D. F. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000205143.16339.cd · Cited by 33
Self-citationPress-blotting on gelatin-coated nitrocellulose membranes
van der Sluis, P. J., Pool, C. W., & Sluiter, A. A. (1987) · Journal of Immunological Methods · doi:10.1016/0022-1759(87)90488-1 · Cited by 31
β‐Amyloid increases somatostatin expression in cultured cortical neurons
Geci, C., How, J., Alturaihi, H., & Kumar, U. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04415.x · Cited by 29
Genetic Epidemiology of Alzheimer Disease
Mayeux, R. P. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200607001-00008 · Cited by 29
Xu, H., & Tian, N. (2008) · The Journal of Comparative Neurology · doi:10.1002/cne.21727 · Cited by 26
Bossers, K., Ylstra, B., Brakenhoff, R. H., Smeets, S. J., Verhaagen, J., & van de Wiel, M. A. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-112 · Cited by 19
Self-citation
Cited by
Single-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 783
Alteration of the microRNA network during the progression of Alzheimer's disease
Lau, P., Bossers, K., Janky, R., Salta, E., Frigerio, C. S., Barbash, S., Rothman, R., Sierksma, A. S. R., Thathiah, A., Greenberg, D., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201974 · Cited by 474
Self-citationNeurodegenerative disease and adult neurogenesis
Winner, B., Kohl, Z., & Gage, F. H. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07613.x · Cited by 405
Metadata
- Authors
- Bossers, K., Wirz, K. T. S., Meerhoff, G. F., Essing, A. H. W., van Dongen, J. W., Houba, P., Kruse, C. G., Verhaagen, J., & Swaab, D. F.
- Affiliations
- Netherlands Institute for Neuroscience (NL)
- Abbott (Netherlands) (NL)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-10-01
- Volume
- 133
- Issue
- 12
- Pages
- 3699-3723
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2084210522
- Cited by
- 230
- References
- 92
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 16 · 2023: 13 · 2022: 18 · 2021: 21 · 2020: 12 · 2019: 15 · 2018: 13 · 2017: 16 · 2016: 13 · 2015: 16 · 2014: 17 · 2013: 23 · 2012: 18
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Top Institute Pharma (T5-207)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- prefrontal cortex, gene expression changes, Braak staging, neurofibrillary tangles, amyloid plaques, amyloid-beta, synaptic activity, synaptic plasticity, APOE ε4, APP processing, mild cognitive impairment, presymptomatic stage
- MeSH terms
- Aged, Aging, Alzheimer Disease, Apolipoproteins E, Female, Multigene Family, Humans, Immunohistochemistry, Male, Synaptic Transmission, Nucleic Acid Hybridization, RNA, Transcription, Genetic, Blotting, Western, Gene Expression, Amyloid beta-Peptides, Prefrontal Cortex, Disease Progression, Reverse Transcriptase Polymerase Chain Reaction, Sirtuins, Microarray Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.